Anti-ACSL1 antibody [EPR13498],Abcam,AB178419

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

IHC-P, WB

Platform ID

BAB832268579

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NameAnti-ACSL1 antibody [EPR13498]
Cat. No.AB178419
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationIHC-P, WB
ClonalityMonoclonal
Clone NumberEPR13498
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation (PubMed : 21242590, PubMed : 22633490, PubMed : 24269233). Preferentially uses palmitoleate, oleate and linoleate (PubMed : 24269233). Preferentially activates arachidonate than epoxyeicosatrienoic acids (EETs) or hydroxyeicosatrienoic acids (HETEs) (By similarity). See full target information ACSL1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.